Company Description
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility.
It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis.
The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024.
HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 15, 2022 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Andrew Simpson |
Contact Details
Address: 550 Reserve Street, Suite 360 Southlake, Texas 76092 United States | |
| Phone | 682-237-7781 |
| Website | heartsciences.com |
Stock Details
| Ticker Symbol | HSCS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| IPO Price | $4.25 |
| CIK Code | 0001468492 |
| CUSIP Number | 42254E104 |
| ISIN Number | US42254E1047 |
| Employer ID | 26-1344466 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Andrew Simpson | Chief Executive Officer, President and Chairman of the Board of Directors |
| Danielle Watson | Chief Financial Officer and Treasurer |
| Mark T. Hilz | Chief Operating Officer, Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| Jun 3, 2025 | 8-K | Current Report |
| May 28, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 15, 2025 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-Q | Quarterly Report |